自2024年至今，越来越多的上市公司新任董秘名单中，出现了前金融从业者。相较于券商投行人士、分析师等，基金经理转行担任上市公司董秘岗位的案 例并不多见。部分案例也说明了基金经理转型已不限于资管领域。 公告未披露新任董秘姜英的薪酬情况，前任董秘韩风生2024年薪酬为84.57万元。 10月13日，罗欣药业发布关于聘任董事会秘书的公告，显示聘任姜英为董事会秘书。 资料显示，姜英出生于1987年，为北京大学理学、经济学双学位本科，北京大学管理学硕士及香港大学金融学硕士。姜英曾主要任职于国金证券资产管理 分公司、光大保德信基金担任分析师，于国泰基金担任分析师、基金经理助理、基金经理，无上市公司董秘工作经验。 Wind资料显示，姜英此前管理国泰科创板两年定开、国泰中小盘成长和国泰金牛创新成长。截至离任前，姜英管理的国泰科创板两年定开和国泰中小盘 成长的规模分别为1.49亿元、4.37亿元，任职回报分别为-12.48%、-34.28%，回报排名为633/2680、2200/2715。 官网显示，罗欣药业创始于1988年，产品覆盖胃肠疾病、儿科、呼吸科、肿瘤、心血管、神经系统、内分泌、解热镇痛类、妇科等领域。另外，罗欣药业 ...

Financial Overview - The company reported total revenue of CNY 152,074,731.41 for the first half of 2025, a decrease from CNY 221,933,271.08 in the same period of 2024, representing a decline of approximately 31.4% [4][5] - Total operating costs for the first half of 2025 were CNY 197,899,171.63, down from CNY 228,077,115.52 in the previous year, indicating a decrease of about 13.3% [4][5] - The net profit for the first half of 2025 was CNY 105,176,469.82, compared to a net profit of CNY 5,475,173.86 in the first half of 2024, showing a significant increase [5][6] Assets and Liabilities - Total assets at the end of the first half of 2025 amounted to CNY 1,504,030,958.30, down from CNY 1,757,857,969.48 at the beginning of the period, reflecting a decrease of approximately 14.4% [3][4] - Total liabilities decreased to CNY 318,614,658.60 from CNY 647,661,753.51, a reduction of about 50.8% [3][4] - The total equity attributable to shareholders increased to CNY 1,185,416,299.70 from CNY 1,110,196,215.97, marking an increase of approximately 6.7% [4][5] Cash Flow - The net cash flow from operating activities for the first half of 2025 was CNY 27,896,651.19, compared to CNY 32,398,357.90 in the same period of 2024, indicating a decrease [6][7] - Cash flow from investing activities showed a net inflow of CNY 175,946,706.63, a significant improvement from a net outflow of CNY 4,386,493.11 in the previous year [6][7] - Cash flow from financing activities resulted in a net outflow of CNY 314,596,678.34, compared to a net outflow of CNY 61,901,761.80 in the same period of 2024 [6][7] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 were both CNY 0.14, compared to CNY 0.01 in the same period of 2024, indicating a substantial increase in profitability per share [5][6]

Group 1 - The stock price of Huahai Pharmaceutical closed at 22.72 yuan on July 30, down 1.43% from the previous trading day [1] - The stock reached a high of 24.24 yuan and a low of 22.55 yuan during the day, with a volatility of 7.33% [1] - The trading volume was 606,356 hands, with a total transaction amount of 1.406 billion yuan [1] Group 2 - Huahai Pharmaceutical operates in the chemical pharmaceutical industry, covering the research, production, and sales of active pharmaceutical ingredients and formulations [1] - The company is based in Zhejiang and its products are involved in cardiovascular, psychiatric, and antiviral fields [1] - During the early trading session on July 30, the stock experienced a rapid rebound, with price fluctuations exceeding 2% within five minutes [1] Group 3 - The main funds showed a slight net inflow on that day [1]

Group 1 - The event "Diplomats in Beijing" was successfully held at Shougang Park, showcasing the transformation of the industrial site into a cultural and tourism landmark, attracting diplomats from 22 countries [1][3] - The Shougang Group and Shijingshan District representatives presented their business development and cooperation needs, highlighting sustainable utilization of industrial heritage and attracting high-tech industries [2] - The event emphasized the innovative integration of digital technology and cultural heritage, with diplomats expressing admiration for the transformation and its potential as a model for other regions [1][3] Group 2 - The Shougang Park has retained its industrial characteristics while incorporating modern living functions, impressing diplomats with its dual focus on heritage and modernization [3] - The series of "Diplomats in Beijing" activities aims to promote high-quality development in the capital and foster international cooperation across various sectors, including trade, technology, and culture [3]

Group 1: Event Overview - The event "Diplomats in Beijing" was successfully held, co-hosted by the Beijing Municipal Foreign Affairs Office, Shijingshan District Government, and Shougang Group, with participation from diplomats from 22 countries [1] - Diplomats visited the Shougang Park, which has transformed from an industrial site to a cultural and tourism hub, showcasing the successful revitalization of urban areas [1] Group 2: Company Presentations - Shougang Group and local enterprises presented their business development and cooperation needs, highlighting sustainable utilization of industrial heritage and attracting high-tech industries [2] - Companies showcased innovative products, including ultra-lightweight robotic arms and smart medical devices, emphasizing their contributions to technological advancement [2] Group 3: Future Cooperation - Diplomats engaged in practical discussions with Shougang Group and local enterprises about economic cooperation and technology integration, with some exchanging contact information for further collaboration [3] - The event served as a platform for promoting high-quality development in Beijing and fostering international cooperation across various sectors [3]